{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-068709","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2025-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.426187+00:00","generated_at":"2026-05-18T05:54:42.668638+00:00","sec_items":["3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"BrainStorm delisted from Nasdaq; shares to trade on OTCQB from July 18","bullets":["Delisting due to non-compliance with Nasdaq minimum shareholder equity rule (Rule 5550(b)(1)).","Nasdaq trading suspended at open on July 18, 2025; company received notice on July 16.","Shares approved for OTCQB quotation under same symbol BCLI starting July 18.","CEO states delisting does not alter mission; focus on NurOwn Phase 3b trial under SPA with FDA.","Company confirms no impact on business operations or ongoing R&D efforts."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-068709","json":"https://secwatch.observer/filing/0001104659-25-068709.json","markdown":"https://secwatch.observer/filing/0001104659-25-068709.md","text":"https://secwatch.observer/filing/0001104659-25-068709.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/tm2521145d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T05:54:42.668638+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8d3240fc79524f6c9f5703a26c406b6dfdcf273","claim":"BRAINSTORM CELL THERAPEUTICS INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics Inc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of trading on July 18, 2025. The Company has applied and been approved to have its common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001213900-26-062844","ticker":"ADTX","company_name":"Aditxt, Inc.","filed_at":"2026-05-29T20:21:24+00:00","headline":"Aditxt receives Nasdaq deficiency for negative equity; delisting hearing set for June 11","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062844","json":"https://secwatch.observer/filing/0001213900-26-062844.json","markdown":"https://secwatch.observer/filing/0001213900-26-062844.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/ea0292786-8k_aditxt.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 27, 2026, Aditxt, Inc. (the “Company”)\nreceived a letter (the “Letter”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market\nLLC (“Nasdaq”) notifying the Company that, based on the stockholders’ equity of $(35,174,386) reported in the Company’s\nQuarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”), the Company no longer satisfies the minimum\nstockholders’ equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1)\n(the “Stockholders’ Equity Requirement”). The Letter further","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1726711/000121390026062844/0001213900-26-062844-index.htm"}},{"accession":"0001104659-26-066974","ticker":"LIMN","company_name":"Liminatus Pharma, Inc.","filed_at":"2026-05-27T20:30:41+00:00","headline":"Liminatus Pharma receives Nasdaq delisting notice; appeals filed","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066974","json":"https://secwatch.observer/filing/0001104659-26-066974.json","markdown":"https://secwatch.observer/filing/0001104659-26-066974.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/tm2615785d1_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 20, 2026, the Company received a notice\nfrom Nasdaq stating that the Company had not regained compliance with the MVLS Rule and the MVPHS Rule. Accordingly, its securities will\nbe delisted from The Nasdaq Global Mark","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1971387/000110465926066974/0001104659-26-066974-index.htm"}},{"accession":"0001213900-26-060267","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-22T01:40:52+00:00","headline":"AIFA gets Nasdaq delisting notice for late filings; later files FY 2025 10-K","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-060267","json":"https://secwatch.observer/filing/0001213900-26-060267.json","markdown":"https://secwatch.observer/filing/0001213900-26-060267.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/ea0291955-8k_allinfuture.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 19, 2026, All In FutureTech Alliance,\nInc. (formerly known as Allied Gaming & Entertainment Inc., the “Company”) received a deficiency letter (the “Letter”)\nfrom the Listing Qualifications Department (the “Staff”) of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026060267/0001213900-26-060267-index.htm"}},{"accession":"0001829126-26-005568","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-21T20:15:19+00:00","headline":"Picard Medical Q1 revenue up 85% to $1.2M; reports $1.4M negative equity, NYSE listing notices","event_type":"other_material","sec_items":["2.02","3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-005568","json":"https://secwatch.observer/filing/0001829126-26-005568.json","markdown":"https://secwatch.observer/filing/0001829126-26-005568.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"reviously disclosed, on May\n8, 2026, the Company received a notice that it was not in compliance with Section 1003(a)(ii) (the “May 8 Notice,” and together\nwith the May 15 Notice, the “ Notices ”). In connection with the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626005568/0001829126-26-005568-index.htm"}},{"accession":"0001213900-26-059270","ticker":"XXI","company_name":"Twenty One Capital, Inc.","filed_at":"2026-05-20T12:49:08+00:00","headline":"Tether International acquires SoftBank's stake in Twenty One Capital; board members resign","event_type":"other_material","sec_items":["1.02","3.01","5.02","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-059270","json":"https://secwatch.observer/filing/0001213900-26-059270.json","markdown":"https://secwatch.observer/filing/0001213900-26-059270.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/ea0291071-8k_twenty.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"o independent directors, the minimum number required during the transition period\nfor compliance with Section 303A.07(a) of the NYSE Listed Company Manual, as provided in Section 303A.00 of the NYSE Listed Company Manual","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070457/000121390026059270/0001213900-26-059270-index.htm"}},{"accession":"0001493152-26-023889","ticker":"GCTK","company_name":"Glucotrack, Inc.","filed_at":"2026-05-15T20:45:37+00:00","headline":"Glucotrack receives second Nasdaq delisting notice; plans to appeal by May 18","event_type":"other_material","sec_items":["3.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023889","json":"https://secwatch.observer/filing/0001493152-26-023889.json","markdown":"https://secwatch.observer/filing/0001493152-26-023889.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/0001493152-26-023889-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 15, 2026, the Company received a second letter from Nasdaq notifying the Company that its Form 10-Q for the period ended March\n31, 2026, indicates that the Company no longer meets the $2,500,000 minimum stockholders’","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1506983/000149315226023889/0001493152-26-023889-index.htm"}},{"accession":"0001437749-26-016455","ticker":"BKYI","company_name":"BIO KEY INTERNATIONAL INC","filed_at":"2026-05-12T20:46:03+00:00","headline":"BIO-key receives Nasdaq delisting notice; stock to move to OTC Markets on May 13","event_type":"other_material","sec_items":["3.01","7.01","9.01"],"materiality_score":0.95,"calibrated_materiality_score":0.95,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-016455","json":"https://secwatch.observer/filing/0001437749-26-016455.json","markdown":"https://secwatch.observer/filing/0001437749-26-016455.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/bkyi20260512_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 6, 2026, BIO-key International, Inc. (the “ Company ”) received notice from the staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) stating that the Company had not regained compliance with Nasdaq Listing Rule 5550(a)","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1019034/000143774926016455/0001437749-26-016455-index.htm"}},{"accession":"0001829126-26-004960","ticker":"PMI","company_name":"Picard Medical, Inc.","filed_at":"2026-05-11T21:08:14+00:00","headline":"Picard Medical raises $5M in public offering, receives NYSE American delisting notice for low equity","event_type":"other_material","sec_items":["1.01","3.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004960","json":"https://secwatch.observer/filing/0001829126-26-004960.json","markdown":"https://secwatch.observer/filing/0001829126-26-004960.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/picardmedical_8k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"July 16, 2025, Brainstorm Cell Therapeutics\nInc. (the “ Company ”) was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as\na result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist\nthe Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock\neffective at the open of trading on July 18, 2025. The Company has applied and been approved to have\nits common stock quoted on the OTC Markets’ OTCQB® market tier, an electronic quotation service operated by OT","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465925068709/0001104659-25-068709-index.htm","comparable_excerpt":"May 8, 2026, the Company received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. The Notice states that the Company reported a stockholders’ equity of approximately $3.8 million as of","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626004960/0001829126-26-004960-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}